This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Tafluprost ocular


Eye drops containing tafluprost.

Drugs List

  • SAFLUTAN 15microgram/ml eye drops
  • SAFLUTAN 15microgram/ml unit dose eye drops
  • tafluprost 15microgram/ml eye drops
  • tafluprost 15microgram/ml unit dose eye drops
  • Therapeutic Indications


    Treatment of elevated intraocular pressure in ocular hypertension
    Treatment of elevated intraocular pressure in open-angle glaucoma

    Reduction of elevated intraocular pressure in ocular hypertension or in open angle glaucoma; as monotherapy in patients intolerant or insufficiently responsive to first line therapy; as adjunctive to beta-blockers.



    Instil 1 drop into the affected eye(s) once daily in the evening.


    Children under 18 years

    Precautions and Warnings

    Females of childbearing potential
    Predisposition to iritis
    Predisposition to uveitis
    Risk factors for cystoid macular oedema
    Anterior chamber lens
    Congenital glaucoma
    Hepatic impairment
    Narrow angle glaucoma
    Neovascular glaucoma
    Pigmentary glaucoma
    Pseudoexfoliative glaucoma
    Pseudophakia with open angle glaucoma
    Pseudophakia with torn posterior lens capsule
    Renal impairment
    Severe asthma

    Advise patient blurred vision may affect ability to drive/operate machinery
    Advise patient hair growth may occur on areas of skin repeatedly exposed
    In combined therapy, administer eye products at least five minutes apart
    To reduce systemic absorption compress lacrimal sac during administration
    Advise patient that some eye changes may be permanent
    Female: Ensure adequate contraception during treatment
    Advise patient not to exceed stated dose
    Advise patient to avoid touching the eye/other surfaces with container tip
    Before initiating treatment inform patient of possibility of eyelash growth
    Before initiating treatment inform patient of risk of eyelid skin darkening
    Before starting treatment inform patient of risk of increased iris pigment

    Pregnancy and Lactation


    Use tafluprost with caution during pregnancy.

    The manufacturer recommends this medication is not used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animals studies have shown reproductive toxicity. At the time of writing there is limited human data available. Risks are unknown.

    Tafluprost must not be used in women of childbearing potential unless adequate contraceptive measures are used.


    Tafluprost is contraindicated during breastfeeding.

    The manufacturer notes tafluprost is not to be used during breastfeeding. Animal studies show excretion of tafluprost and/or its metabolites in breast milk after topical administration. At the time of writing it is unknown if tafluprost and/or its metabolites are excreted in human milk. A decision should be made to discontinue breastfeeding if tafluprost is of greater benefit to the mother.

    Side Effects

    Abnormal sensation in eye
    Aggravation of existing asthma
    Allergic conjunctivitis
    Anterior chamber flare
    Blepharal pigmentation
    Blurred vision
    Cells in anterior chamber of eye
    Conjunctival follicles
    Conjunctival hyperaemia
    Conjunctival oedema
    Conjunctival pigmentation
    Cystoid macular oedema
    Dry eyes
    Eyelash changes
    Eyelid erythema
    Eyelid oedema
    Eyelid sulcus
    Hypertrichosis of eyelid
    Increased iris pigmentation
    Increased lacrimation
    Macular oedema
    Ocular discharge
    Ocular discomfort
    Ocular hyperaemia
    Ocular irritation
    Ocular pain
    Ocular pruritus
    Reduced visual acuity
    Sensation of foreign body in eye
    Superficial punctate keratitis


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2019

    Reference Sources

    Summary of Product Characteristics: Saflutan 15micrograms/ml eye drops, solution in single-dose container. Santen UK Limited. November 2017.

    Summary of Product Characteristics: Saflutan 15micrograms/ml eye drops, solution. Santen UK Limited. February 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.